Clinical trial

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

NCT03083743

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-10-01

PhasePHASE3

Study timeline

Study start (actual)2016-10-01Date precision: month

Registry last updated2017-03-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small-cell Lung Cancer (NSCLC) Stage IVunresolved

Interventions

Recombinant human Apo-2 ligand for InjectionBIOLOGICAL

PlaceboBIOLOGICAL

Sponsors & collaborators

Shanghai Gebaide Biotechnology Co., Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03083743 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.